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a b s t r a c t
Central to the pathogenesis of atypical haemolytic uraemic syndrome (aHUS) is over-activation of the
alternative pathway of complement. Inherited defects in complement genes and autoantibodies against
complement regulatory proteins have been described. The use of plasma exchange to replace non-vailable online 28 June 2013
eywords:
culizumab
aemolytic Uraemic Syndrome
reatment
functioning complement regulators and hyper-functional complement components in addition to the
removal of CFH-autoantibodies made this the ‘gold-standard’ for management of aHUS. In the last 4
years the introduction of the complement inhibitor Eculizumab has revolutionised the management of
aHUS. In this review we shall discuss the available literature on treatment strategies to date.
© 2013 Elsevier Ltd. All rights reserved.omplement
. Introduction
Atypical HUS (aHUS) is the prototypical disease of comple-
ent over activation (Kavanagh et al., 2008a). Thrombocytopenia,
icroangiopathic haemolytic anaemia and acute renal failure are
he hallmarks of haemolytic uraemic syndrome (HUS). Atypical
US is the term used to classify any HUS not due to Shiga toxin
Stx)-producing bacteria, typically Escherichia coliO157:H7 (Besbas
t al., 2006).
The discovery of mutations in the complement system in aHUS
y Warwicker et al. (1998) was to set in train the research which
as to ultimately result in the successful use of the complement
nhibitor Eculizumab in aHUS.
. The complement system
Complement is an ancient pathway that sits at the nexus of the
mmune system (Ricklin et al., 2010): protecting against invading
athogens; bridging innate and adaptive immunity (Kemper and
tkinson, 2007); and disposing of immune complexes and injured
issues and cells (Richards et al., 2007b).
Complement activation ismediatedviadifferent initiating trigg-
rs. The classical pathway (CP) can be initiated via IgM and IgG as
ell as the pattern recognition molecule (PRM) C1q. In the lectin
athway (LP) the PRMs, mannose binding lectin (MBL) and ficolins
ind carbohydrates to trigger complement activation. The alter-
ative pathway (AP) constantly “ticks over” depositing C3b on
∗ Corresponding author at: The Institute of GeneticMedicine, International Centre
or Life, Central Parkway, Newcastle upon TyneNE1 3BZ, UK. Tel.: +44 191 241 8634.
E-mail address: david.kavanagh@ncl.ac.uk (D. Kavanagh).
161-5890/$ – see front matter © 2013 Elsevier Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.molimm.2013.05.224surfaces which is inactivated on host cells and amplified on for-
eign cells. Properdin can also bind to foreign and apoptotic cells
to propagate the AP. The AP is also recruited by C3 convertases
formed by the CP and LP and as such, it serves as an amplification
step accounting for ∼80% of all complement activation regard-
less of the initial trigger (Harboe and Mollnes, 2008). All pathways
subsequently converge to produce the common terminal pathway
effector molecules (Ricklin et al., 2010) (Fig. 1).
The runaway complement activation of the AP has evolved to
rapidly destroy invading microorganisms but to prevent collateral
damage to host tissue, fluid phase (e.g. complement factor H (CFH)
and complement factor I (CFI)) and membrane bound (e.g. mem-
brane cofactor protein (MCP)) complement regulatory proteins are
present. It is an imbalance between this activation and regulation
on the glomerular vasculature which underlies the pathogenesis of
aHUS.
3. The role of complement in aHUS
The last15yearshas seen theelucidationof thecriticalpathways
involved in the pathogenesis of aHUS. Loss of function mutations
in complement regulatory proteins and gain of function mutations
in complement components have been described in aHUS. Simi-
larly, autoantibodies to complement regulatory proteins have been
described.
3.1. Complement factor HCFH is the critical fluid-phase regulator of the AP acting via
its N-terminal domains (CCPs 1–4) (Richards et al., 2007b). CFH
can also protect host surfaces by binding to polyanions such as
the glycosaminoglycans (GAG) of endothelial cells and exposed
200 E.K.S. Wong et al. / Molecular Immunology 56 (2013) 199–212
Fig. 1. Complement activation and the mechanism of action of Eculizumab. The AP constantly undergoes ‘tick-over’ but can also be primed by the CP and LP pathways. The
C3b that is formed interactswith factor B (B), which is then cleaved by factor D to form the AP C3 convertase (C3bBb). This enzyme complex is attached to the target covalently
via C3b while Bb is the catalytic serine protease subunit. Because C3 is the substrate for this convertase, a powerful feedback loop is created. Unchecked, this will lead to
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activation of the terminal complement pathway with generation of the effector m
inds C5 and prevents its entry into the C5 convertase (C3bBbC3b), thus precluding
asement membranes (Meri and Pangburn, 1994; Schmidt et al.,
008). CFH has two GAG binding domains in CCPs 6–8 and CCPs
9–20 which have different sulphate specificities. CCPs 6–8 are
redominantly responsible for binding in the eye while the C-
erminal domains (CCPs 19–20) account for kidney binding (Clark
t al., 2013). Additionally CFH also binds to the lipid peroxidation
roductmalondialdehyde (Weismann et al., 2011), the acute phase
roteins, C-reactive protein (Hakobyan et al., 2008; Laine et al.,
007; Sjoberg et al., 2007) and pentraxin 3 (Kopp et al., 2012) as
ell as necrotic cells (Sjoberg et al., 2007).
Mutations in CFHwere first described in 1998 (Warwicker et al.,
998) andmutations in this gene are themost commongenetic pre-
isposition to aHUS, accounting for around25%of all cases (Caprioli
t al., 2001; Dragon-Durey et al., 2004; Fan et al., 2013; Geerdink
t al., 2012; Maga et al., 2010; Neumann et al., 2003; Perez-
aballero et al., 2001; Richards et al., 2001;Warwicker et al., 1998).
he majority of mutations in CFH are located in CCPs 19–20 and
o not usually result in a quantitative deficiency. These C-terminal
utations fail to bind to cell surfaces and result in ineffective
ontrol of complement activation on the glomerular vasculature
Abarrategui-Garrido et al., 2008; Ferreira et al., 2009; Vaziri-Sani
t al., 2006). C-terminal CFH mutants have also been demon-
trated to have reduced binding to platelets resulting in increased
omplement activationwith consequent platelet activation, aggre-
ationand releaseof tissue factor-expressingmicro-particles (Stahl
t al., 2008). Although clustering in the C-terminal, mutations are
eported throughout the molecule. N-terminal mutations in CFH
CCPs 1–4) result in ineffective control of the AP both in the fluid
hase and on cell surface (Pechtl et al., 2011). The functional effects
f normally secreted genetic variants in other regions of the protein
emain to be determined (Kavanagh andAnderson, 2012; Tortajada
t al., 2012).
CFH and the five factor H-related proteins, which arose from
everal large genomic duplications, reside in the RCA cluster. This
omologypredisposes togene conversions andgenomic rearrange-
ents through non-allelic homologous recombination (NAHR) and
icrohomology-mediated end joining (MMEJ). The CFH mutations
1191L, V1197A, and combined S1191L/V1197A arose through
ene conversion between CFHR1 and CFH (Heinen et al., 2006). A
ybrid (fusion) gene comprising the 21 N-terminal exons of CFH
nd the2C-terminal exonsofCFHR1hasbeendemonstrated tohave
risen throughNAHRresulting inaHUS (Venables et al., 2006).More
ecently a hybrid gene consisting of the 22N-terminal exons of CFH
nd the 5 C-terminal domains of CFHR3 arising through MMEJ hases; the anaphylatoxin C5a and the membrane attack complex (MAC). Eculizumab
age into the effector molecules, C5a and C5b and ultimately the MAC.
been reported in aHUS (Francis et al., 2012). As with C-terminal
point mutations in CFH, these hybrid genes result in loss of cell
surface complement regulation.
3.2. Complement factor I
CFI is a serumserineprotease,which functions as a criticalmedi-
ator of complement regulation by cleaving C3b and C4b in the
presence of its cofactors (CFH for C3b; C4BP for C4b; MCP and CR1
for both). It is predominantly synthesised by the liver. Mutations
in CFI account for between 5 and 10% of aHUS (Caprioli et al., 2006;
Fremeaux-Bacchi et al., 2005; Kavanagh et al., 2005, 2008b; Maga
et al., 2010; Nilsson et al., 2010, 2007; Sullivan et al., 2010; Westra
et al., 2010). The CFI mutations described in aHUS are all heterozy-
gous. These mutations cluster in the serine protease domain and
the majority result in a non-secreted protein. Functional analysis
has been undertaken for a number of mutants and demonstrates a
loss of both AP and CP regulatory activity in the fluid phase and on
cell surfaces (Kavanagh et al., 2008b; Nilsson et al., 2010).
3.3. Membrane cofactor protein
MCP is a surface bound complement regulatory protein which
acts as a cofactor for the CFI mediated cleavage of C3b and C4b that
are deposited on host cells (Richards et al., 2007a). Mutations in
MCP are found in around 10% of patients with aHUS (Caprioli et al.,
2006; Fremeaux-Bacchi et al., 2006; Maga et al., 2010; Richards
et al., 2007a, 2003; Westra et al., 2010). Most mutations described
in aHUS reside in the extracellular 4 CCP domains that are respon-
sible for C3b and C4b binding. Most MCP mutations described to
date result in a quantitative defect in MCP (∼75%) (Richards et al.,
2007a). The remainingmutationshavebeendemonstrated to result
in a secreted, non-functional protein (Richards et al., 2007a).
3.4. Activating mutations
In addition to loss of function mutations in complement regu-
latory proteins, gain of function mutations have been described in
the complement components C3 and factor B (CFB). C3 is cleaved
to form the anaphylatoxin C3a and C3b, which is highly reactive,
and can bind to cell surfaces via its reactive thioester. C3b can
then interact with CFB in the presence of factor D to form the
AP C3 convertase (C3bBb), which cleaves further C3, introducing
a positive-amplification loop (Fig. 1).
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Gain of function mutations in CFB are rare (Fan et al., 2013;
eerdink et al., 2012; Goicoechea de Jorge et al., 2007; Kavanagh
t al., 2006; Noris et al., 2010; Roumenina et al., 2009; Tawadrous
t al., 2010). The mutations have been demonstrated to either
nhance formation of the C3bB proenzyme or form a C3 conver-
ase more resistant to decay by the complement regulators decay
ccelerating factor (DAF; CD55) andCFH (Goicoechea de Jorge et al.,
007; Roumenina et al., 2009). Ultimately thesemutations result in
ncreased complement deposition on endothelial cells (Roumenina
t al., 2009).
Mutations in C3 appear to be more common occurring in 2–10%
f aHUS (Fan et al., 2013; Fremeaux-Bacchi et al., 2013, 2008;
eerdink et al., 2012; Lhotta et al., 2009; Maga et al., 2010; Noris
t al., 2010; Roumenina et al., 2012; Sartz et al., 2012). As with CFB
utations, the C3 mutants either have increased resistance to reg-
lation or bind to CFB with higher affinity resulting in increased
3 convertase formation (Roumenina et al., 2012; Sartz et al.,
012). These mutations result in increased complement activa-
ion on platelets (Sartz et al., 2012) and glomerular endothelium
Roumenina et al., 2012)
.5. Acquired complement abnormalities in aHUS
As well as the genetic abnormalities described in aHUS, autoan-
ibodies to CFH have also been linked to disease in 4–14% of aHUS
atients (Abarrategui-Garrido et al., 2009; Dragon-Durey et al.,
005; Foltyn Zadura et al., 2012; Jozsi et al., 2007; Maga et al.,
010; Moore et al., 2010; Noris et al., 2010). In cohorts of pae-
iatric patients, this figure is as high at 25% (Hofer et al., 2012).
ost of the reported studies suggest that the anti-CFH Abs bind
redominantly to the C-terminus (Dragon-Durey et al., 2005; Jozsi
t al., 2007; Moore et al., 2010) although in some cases there is
polyclonal response (Blanc et al., 2012). Cross reactivity of the
nti-CFH Ab has also been seen to CFHR1 (Blanc et al., 2012; Moore
t al., 2010; Strobel et al., 2011) and CFHR2 (Blanc et al., 2012). Sev-
ral studies have demonstrated various functional consequences
f anti-CFH Abs. The antibodies have been demonstrated to reduce
inding to C3b (Blanc et al., 2012; Jozsi et al., 2007). They perturb
FH-mediated cell surface protection and in some individuals the
utoantibodies also impair cofactor activity (Blanc et al., 2012) or
ecay accelerating activity (Dragon-Durey et al., 2004). These func-
ional studies suggest a pathogenic role for CFH autoantibodies in
HUS.
Autoantibodies to CFI are much rarer than anti-CFH Abs (0–2%)
FoltynZaduraet al., 2012;Kavanaghet al., 2012).Anti-CFIAbswere
een to form immunecomplexes in serumhowever functional anal-
sis revealed only a minor effect on fluid phase co-factor activity
Kavanagh et al., 2012). The co-existence of functionally significant
utants in themajority of patients, added to the lack of correlation
f anti-CFI Ab titre and disease activity raise the possibility that
hey are an epiphenomenon rather than a direct cause of disease.
. Incomplete penetrance
Incomplete penetrance has been reported for all the genes asso-
iated with aHUS. Penetrance has been reported at around 50%
or individuals carrying CFH, CFI, MCP, and CFB mutations (Caprioli
t al., 2003;KavanaghandGoodship, 2010; Sullivanet al., 2011) and
lightly lower for C3 mutations, albeit with small numbers (Lhotta
t al., 2009). This suggests that the penetrance is altered by other
nvironmental and genetic modifiers.
It is increasingly recognised that patients may have mutations
nmore than one complement gene (Bienaime et al., 2010; Cruzado
t al., 2009; Esparza-Gordillo et al., 2006;Maga et al., 2010; Sellier-
eclerc et al., 2007) or mutations in one complement gene in
ddition to autoantibodies to complement regulators (Kavanaghunology 56 (2013) 199–212 201
et al., 2012; Moore et al., 2010). In a study of 795 aHUS patients
the European Working Party on Complement Genetics demon-
strated that at least 3.4% of aHUS cases will have more than one
mutation. 8–10% of patients with mutations in CFH, C3 or CFB had
combined mutations whereas 25% of patients with mutations in
CFI orMCP had combinedmutations (Bresin et al., 2013). The pene-
trance increased as the number of mutations in a patient increased
(Bresin et al., 2013).
In addition to mutations in complement genes a number
of single nucleotide polymorphisms (SNPs) in CFH have been
demonstrated to be associated with aHUS in several studies
(Abarrategui-Garrido et al., 2009; Caprioli et al., 2003; Ermini et al.,
2012; Esparza-Gordillo et al., 2005; Fremeaux-Bacchi et al., 2005;
Pickeringet al., 2007).Ahaplotype inCFH (CFH-H3; tgtgt) composed
of these SNPs increases this risk of aHUS 2–4-fold (Fremeaux-
Bacchi et al., 2013; Pickering et al., 2007). A haplotype block in
MCP (MCPggaac) comprising 2 SNPs in the promoter region has
been associated with a 2–3 fold increased risk of aHUS (Esparza-
Gordillo et al., 2005; Fremeaux-Bacchi et al., 2013, 2005). Some
of these studies have suggested that this risk occurs exclusively
in those patients already carrying complement mutations (Ermini
et al., 2012; Esparza-Gordillo et al., 2005). A SNP in C4b binding
protein (R240H) was associated with aHUS in cohorts from the UK
and France but could not be replicated in a Spanish cohort (Blom
et al., 2008; Martinez-Barricarte et al., 2009). In a study examining
SNPs in 47 complement genes in 2 separate cohorts, SNPs in CFHR2
and CFHR4were also associatedwith aHUS. In this study therewere
no reproducible associations between SNPs and aHUS outside the
RCA cluster (Ermini et al., 2012).
Thus, haplotypes and SNPs act together with mutations and
inhibitory autoantibodies to increase the penetrance of disease.
However even when a patient has multiple genetic risk factors,
disease may not present until middle age suggesting a triggering
stimuli is required fordisease tomanifest. In individualswithmuta-
tions, these stimuli have been suggested to be upper respiratory
tract infections, fevers, pregnancy, drugs and non Escherichia coli
diarrhoeal illnesses as potential triggers (Bento et al., 2010; Caprioli
et al., 2006; Edey et al., 2008; Fakhouri et al., 2010; Fremeaux-
Bacchi et al., 2013; Goodship and Kavanagh, 2010; Noris et al.,
2010). It is likely that these events trigger the APwhich susceptible
individuals are unable to adequately control, resulting in aHUS.
5. Diacylglycerol kinase ε and HUS
In addition to complement mediated aHUS (Lemaire et al.,
2013) have recently demonstrated that homozygous or compound
heterozygous mutations in diacylglycerol kinase  (DGKε) cause
disease. The clinical phenotype of these patients appears distinct
from complement mediated aHUS. All individuals presented with
aHUSbeforeoneyear (mean0.5 years, range0.3–0.9 years). In those
recovering fromtheacuteepisodeof aHUS,microscopichaematuria
and proteinuria persisted and progression to CKD was common. In
keepingwith this distinct phenotype, a recessively inheritedMPGN
like illness with proteinuria and renal failure has also been linked
to DGKε (Ozaltin et al., 2013). In contrast to serum complement
mediated aHUS, recurrence in renal transplants was not seen.
6. Diagnosing aHUS
Having diagnosed a thrombotic microangiopathy (TMA), the
initial management involves differentiating between thrombotic
thrombocytopenic purpura (TTP), Stx-HUS, and aHUS (reviewed
Loirat and Fremeaux-Bacchi, 2011). Rapid exclusion by microbio-
logical analysis for Stx-producing E. coli and analysis of ADAMTS13
activity can lead to a diagnosis of aHUS. Following exclusion of
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tx-HUS and TTP, precipitating events and the underlying genetic
efects predisposing to aHUS should be sought.
Prior to initiation of plasma exchange (PE) serum should be
btained for levels of C3, C4, CFH and CFI, and a complement anti-
ody screen. FACS analysis of peripheral blood mononuclear cells
orMCP expression should be performed. Genetic testing including
method to detect copy number variation should be undertaken.
. Prognosis
Historically, the overall prognosis for patients with aHUS has
een poor with up to 48% of children and 67% of adults dying or
eaching end-stage renal disease (ESRD)within 5 years (Fremeaux-
acchi et al., 2013; Noris et al., 2010). The outlook is predicted by
he genotype with MCP mutations carrying the best prognosis. In
everal large cohorts, no patient with anMCPmutation died at first
resentation and at 5 years only 35% had reached ESRD. Mutations
n CFH, CFI or C3 all carry poor outcomes. At 3–5 years follow up,
p to 77% of patients with CFH mutations had developed ESRD or
ad died. Only 30–40% of individuals with CFI and C3 mutations
ill be alive with native kidney function at 3–5 years (Fremeaux-
acchi et al., 2013; Noris et al., 2010). The prognosis of aHUS with
FB mutations is also poor (Goicoechea de Jorge et al., 2007; Noris
t al., 2010; Roumenina et al., 2009).
In addition to predicting the outcome in native kidneys, the
utcome following renal transplantation is determined largely by
he underlying genetic abnormality. Graft failure is predominantly
ue to aHUS recurrencewhich occurs in 60–70% of patients (Bresin
t al., 2006; Le Quintrec et al., 2013). In individuals with mutations
n CFH the recurrence rate is >80%. Similarly activating mutations
n C3 and CFB also have a high risk of renal recurrence. Initial
tudies all suggested that mutations in CFI carried a poor prognosis
lthough more recently one study failed to replicate this data (Le
uintrec et al., 2013). Unlike the serum complement proteins,
he recurrence rate in individuals with mutations in MCP is very
ow (Loirat and Fremeaux-Bacchi, 2008). As MCP is a membrane
egulator, a renal allograft will correct the complement defect and
rotect against aHUS.
. Treatment
.1. Plasma exchange
Until the introduction of Eculizumab, PE has been considered
he ‘gold-standard’ for management of aHUS. The replacement
f non-functioning complement regulators and hyper-functional
omplement components (e.g. gain of function mutations) in addi-
ion to the removal of CFH-autoantibodiesmade PE a logical choice
reviewed in European (Ariceta et al., 2009) and UK (Taylor et al.,
010) guidelines on aHUS treatment). The consensus based guide-
ines recommended that PE should be commenced as soon as
ossible on diagnosis of aHUS and performed daily with dose titra-
ion to control haemolysis. Oncehaemolysis has been controlled, PE
anbe slowlywithdrawn, although individualswith genetic defects
n the complement system are frequently plasma dependent and
equire long term plasma therapy (weekly/biweekly) to maintain
emission. In adults, only once ADAMTS13 deficiency is excluded
hould Eculizumab be considered.
. Eculizumab.1. Pharmacology
Eculizumab is a recombinant, monoclonal antibody directed
gainst human complement component C5 (Rother et al., 2007).unology 56 (2013) 199–212
Molecular modelling has suggested that Eculizumab binds C5
and prevents its entry into the C5 convertase, thus precluding
cleavage into the effector molecules, C5a and C5b (Zuber et al.,
2012a) (Fig. 1).
Eculizumab has been humanized, replacing the murine heavy-
chain constant region with a human hybrid IgG2/IgG4 constant
region (Thomas et al., 1996). This hybrid region utilises the desir-
able properties both of IgG2, which fails to bind Fc receptors
(Canfield and Morrison, 1991), and IgG4, which does not activate
complement (Tao et al., 1993), to reduce the pro-inflammatory
potential of the antibody.
Eculizumab is administered by intravenous infusion and has a
half-life of ∼11 days (Rother et al., 2007). Complete blockade of
the terminal pathway of complement occurs in vivo with serum
concentrations above 35g/mL (Park et al., 2011). Human tissue
cross-reactivity has not been seen in Eculizumab binding studies
(Rother et al., 2007) and little transplacental transfer of Eculizumab
has been reported in pregnant women with paroxysmal nocturnal
haemoglobinuria (PNH) on Eculizumab (Kelly et al., 2010; Luzzatto
et al., 2010).
9.2. Evidence in animal models for the use of Eculizumab in aHUS
Pickering et al. (2007) generated a transgenic mouse lacking
the C-terminal domains of factor H (Cfh−/−16–20). Without the
GAG binding domains, endothelial cell complement regulationwas
lacking and themice spontaneously developed aHUS. Goicochea de
Jorge et al. (2008) subsequently crossed the Cfh−/−16–20 with a
C5-deficient mouse which did not develop aHUS, suggesting a crit-
ical role downstreamof C3b generation in aHUS and thus providing
a rationale for the use of Eculizumab in human disease.
9.3. The use of Eculizumab in aHUS
The use of Eculizumab in aHUS was first reported by Gruppo
and Rother (2009) and Nurnberger et al. (2009) as two separate
cases published in the New England Journal of Medicine in 2009.
In this review, we describe the published experience of the use
of Eculizumab in the treatment of aHUS. In total 44 cases have
been summarised in Tables 1–3. These are limited to individual
case reports and series. Data from prospective clinical trials of
Eculizumab in the treatment of aHUS awaits publication.
9.4. Eculizumab and the treatment of aHUS in native kidneys
There are currently 19 reported cases of the use of Eculizumab
in aHUS in native kidneys (Table 1). Over half were in children
and the oldest patient was 50 years. While the clinical course of
disease leading to the commencement of Eculizumab was vari-
able, responsewas overwhelmingly positive, albeit with the caveat
of publication bias towards successful cases. Plasma exchange
was attempted in 17/19 patients prior to the use of Eculizumab.
Most (13/19) patients had severe renal failure or had already
commenced renal replacement therapy. The time from diagnosis
until use of Eculizumab was variable. There were 6 patients who
received Eculizumab early in their clinical course (<2 weeks). Five
were on dialysis and four patients had some plasma exchange.
The fifth patient described by (Ohanian et al., 2011a,b) had no
plasma exchange – concerns regarding her neurological status
prompted the first-line use of Eculizumab. In a further paedi-
atric case Eculizumab was used as first line treatment successfully
(Gilbert et al., 2013).The general outcome was of an improvement in TMA and most
patients had improvement in their renal function, including many
of those already on dialysis. Povey et al. (2013) reported a case
of a 21-year old unsuccessfully treated with PE who responded
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Table 1
Summary of 18 patients receiving Eculizumab for the treatment of aHUS in the native kidney.
Reference Mutation Age at
onset of
aHUS
Response to PE Time from aHUS
diagnosis to Ecu
Response to PE
at time of Ecu
SCr (mol/L) at
time of Ecu
Achieved TMA
remission
Ecu dosing Evolution of aHUS
last SCr (mol/L)
Follow-up
Gruppo and Rother
(2009)
NI <8d PI sensitive
3 relapses over 11m
19m Resistant 265 Y Ongoing Remission
35
2y 4m
Fremont et al. (2009) CFH 4y PE partially sensitive Months Partially
sensitive
80 Y Ongoing Remission
26
10w
Mache et al. (2009) NI 17.8m PE sensitive
3 relapses at PE taper
3m Resistant Dialysis Y Single dose Relapse 2 weeks
further 3 doses
ESRD
Ecu
discontinued
Kose et al. (2010) NI 18y NK Months Resistant ∼300 Y Single dose Relapse at 2m
ESRD
NA
Lapeyraque et al.
(2011)
CFH S1191L
V1197A
7m PE/PI sensitive
11 relapses over 5 y
Years Resistantb 108 Y Ongoing Remission
44
1y 3m
Prescott et al. (2010) CFI A258T 47y PE sensitive
relapse 2w after PE
cessation
18d Resistant 610 Y Ongoing Remission
230
7m
Ohanian et al.
(2011a,b)
NI 50y NAa 6d No PEa 600 Y Ongoing Remission
125
6m
Tschumi et al. (2011) CFH C611Y 9y 2 relapses during PE
taper
126d Sensitivec 220 Ye Ongoing Remission
∼100
2y
Ariceta et al. (2012) NI 28d Resistant to 4× PI
Intolerant of PE
11d Resistantb Dialysis Y Ongoing Remission
normal SCr
14m
Carr and Cataland
(2012)
CFH 20y Resistant <2w Resistant Dialysis Y 9m Relapse 6m later
Remission again
with Ecu
NK
Cayci et al. (2012) CFI
K434R
10y 10 sessions of PE <2w Resistant Dialysis Y 3× doses Remission
∼44
4m
Garjau et al. (2012) MCP c.286+1G>C 44y PE for 90 days 90d Resistant Dialysis Y 27w ESRD at 27w Ecu
discontinued
Kim et al. (2012) CFH Y1190H 7m 3 relapses despite PE 4m Resistant Dialysis Y. Ongoing Remission
75
18m
Dorresteijn et al.
(2012)
NI 6y Initial response to PE,
relapse on PI
11w Resistant Dialysis Y Ongoing Remission
80
9m
Giordano et al. (2012) CFH c3514G>T 1y 21 PI 3m Resistant Dialysis Y Ongoing Remission
44
12m
Vilalta et al. (2012) CFH D1119N 1y PE sensitive 5m No PEd Dialysis Y Single dose Relapse after 8w
restarted on Ecu
remission 26.5
2.5y
De et al. (2010) and
Heinen et al. (2013)
CFH S1191L 6m PE dependent 11y Sensitive Dialysis Y Ongoing ESRD
Ecu continued to
maintain TMA
remission
NK
Povey et al. (2013) NK NK PE resistant Months Resistant Dialysis Y Ongoing Remission
near-normal SCr
NK
Gilbert et al. (2013) CFB
K323Q
4m NAa 7 days No PEa 20 Y Ongoing Remission
12
6m
NI: not identified; NK: not known; NA: not applicable; SCr serum creatinine; Ecu: Eculizumab; PI plasma infusion; PE plasma exchange.
a Commenced on Ecu first line.
b Was receiving plasma infusion.
c Stopped due to allergic reaction.
d PE previously stopped due to intolerance.
e Already in remission when Ecu commenced.
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Table 2
Summary of 15 patients receiving Eculizumab for the treatment of aHUS recurrence following renal transplantation.
Reference Mutation Previous
transplants
Age and post-Tx
course
Time from
recurrence
to Ecu
SCr (mol/L) at
time of Ecu
Eculizumab
dosing
TMA remission
achieved
Recurrence if
Ecu stopped
Outcome Ecu
continued SCr
(mol/L)
Follow up
Nurnberger et al. (2009) CFH Y475S 1st Tx recurrence
at 5w, PE resistant,
graft loss
37y
2nd Tx, recurrence
at 6w.
PE resistant
5d 132 Single dose Y Likely (21m)
graft loss
NA NA
Chatelet et al. (2010) C3
R570Q
1st Tx, recurrence
at 5m
Graft loss at 2y.
43y
2nd Tx,
recurrence at 3y,
PE dependent
15m 320 Ongoing Y NA 2 recurrences
of TMAb
230
2y 5m
Legault and Boelkins
(2009)
ND No 34y
1st Tx recurrence
at 1m and 5m.
PE sensitive then
resistant
9m 323 Ongoing Y NA Remission
238
6m
Davin et al. (2010) CFH S1191L 1st Tx, recurrence
at 3d,
graft loss.
2nd Tx under PE,
recurrence at 10w
graft loss
17y
3rd Tx,
prophylactic PE.
Recurrence at 4m.
rescue PE
intolerant at 10m.
10m 131 Ongoing Ya NA Remission
130
1y 10m
Larrea et al. (2010) and
Loirat and
Fremeaux-Bacchi
(2011)
NI No 22y
1st Tx recurrence
at 12d PE resistant
9d 415 Single dose Y Recurrence
(11.5m)
Ecu resumed
Subsequent
humoral
rejection
Ecu stopped
and graft loss
NA
Zuber et al. (2011) CFH 1st Tx, recurrence,
graft loss
24y
2nd Tx,
prophylactic PI/PE
recurrence 1d
PE resistant
4d 500 Ongoing Y NA Remission
62
9m
Al-Akash et al. (2011) C3
R570W
1st Tx, recurrence
at 4y,
graft loss
2nd Tx recurrence
at 2m
graft loss
15y
3rd Tx,
prophylactic PE,
recurrence at 2m,
PE partially
sensitive
∼20d 202 Ongoing Y NA Remission
115
1y 5m
Duran et al. (2012) CFH Q1172X No 32y
1st Tx,. recurrence
at 1m
PE sensitive
further recurrence
at 2m
1m Dialysis Ongoing Y NA Remission
228
10m
Alachkar et al. (2012) NI 1st Tx recurrence
2m, graft loss
32y
2nd Tx
recurrence at 10
weeks.
PE resistant
∼2w Dialysis 8m Y Recurrence 5m
after Ecu
stopped –
pneumoniac
Ecu restarted
but graft loss
after ATN.
Ecu
discontinued
NA
Ardissino et al. Zuber
et al. (2012b)
CFH No 6y
1st Tx,
recurrence 2m,
PE resistant
2d 442 Ongoing Y NA Remission
48
25m
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Zuber et al. (2012b) CFH S1191L
V1197A
1st Tx recurrence,
graft loss
23 y
2nd Tx
recurrence 3d.
PE resistant
3d 627 Ongoing Y NA Remission
65
17m
Zuber et al. (2012b) CFH/CFHR1
hybrid
4 previous Tx – 2
due to recurrence,
2 due to
thrombosis
27y
5th Tx,
recurrence 3d
PE partially
sensitive
1m 237 Ongoing Y Fresh TMA
lesions at 3
monthsd
Remission
204
12m
Zuber et al. (2012b) Anti FH Ab
CFHR1/3
4 previous Tx, 3
due to recurrence
41y
5th Tx,
recurrence 5ye
PE partially
sensitive
3m 89 Ongoing Y NA Remission
80
9m
Guentin et al.
Zuber et al. (2012b)
CFI
G101R
1st Tx, recurrence
graft loss
42y
2nd Tx,
15m of
prophylactic PE,
8m taper
recurrence at 13m
after stopping.
PE resistant
9w 190 Ongoing Y Relapse
following delay
prior to 5th
infusion
Remission
156
4.5m
Heyne
Zuber et al. (2012b)
NI 1st Tx recurrence
graft loss
43y
2nd Tx,
recurrence 8d
no PE
1d 176 8m Y Relapse 3
months after
stopping
influenza
vaccine
triggered
Remission
123
14m
NI: not identified; ND: not documented; Tx: renal transplant; Ecu: Eculizumab; SCr: serum creatinine.
a In remission already.
b aHUS recurrence with AKI when injection delayed by 6–8 days.
c Following Ecu resumption, patient had endovascular procedure leading to severe ATN and subsequent graft loss.
d Biopsy of transplant allograft in response to falling haptoglobin level.
e Graft biopsy due to slight decrease in renal function disclosed fresh TMA lesions.
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Table 3
Summary of 10 patients who received Eculizumab as pre-emptive treatment for aHUS in renal transplantation.
Reference Mutation Previous
transplants
Age (y) at
current Tx
Type of donor Received PEa When Eculizumab
starteda
Outcome SCr
(mol/L)
Follow Up
Zimmerhackl et al. (2010) CFH
W1183C
No 10 DD 9 PE
day 0 to day 9
Day 10 No recurrence
44
2y 1m
Weitz et al. (2011) CFH
E1198X
No 7 DD No Day-21b No recurrence
normal SCr
7m
Nester et al. (2011) CFH/CFHR1 hybrid No 12 LNR 2 PE
day-7 and day-1
Day 7 and -1 No recurrence
80
4m
Krid et al. (2012) CFH/CFHR1 hybrid No 7.5 DD No At time of
transplant
No recurrence
normal SCr
16m
Rondeau et al. Zuber et al.
(2012b)
Complex
recombination
between CFH and
CFHR1
No 18 DD 6PE
day 0 to day 5
Day 5 No recurrence 14m
Lahoche Zuber et al. (2012b) C3
R161W
No 6.4 DD No At time of
transplant
No recurrence
44
4.5m
Krid and Niaudet Zuber et al.
(2012b)
CFH
Q1137X
No 9 DD No At time of
transplant
No recurrence
58
2m
Hourmant Zuber et al. (2012b) CFH
S1191L
1st Tx, recurrence. 18 DD 1PE
day 0
At time of
transplantc
Graft lossd NA
Zuber and Legendre Zuber
et al. (2012b)
CFH
Y1177C
1st and 2nd Tx
recurrence
41 DD No At time of
transplant
No recurrence
176
2m
Xie et al. (2012) CFH
E625X
No 30 LNR 2PE
day-7 and day-1
Day-7 and day-1 No recurrence
∼77
1y
NA: not applicable; DD: deceased donor; LNR: live non-related donor; SCr: serum creatinine; Ecu: Eculizumab.
a Timings in days in relation to day of renal transplantation.
b Received weekly doses until transplantation.
c Discontinued after nephrectomy.
d Early arterial thrombosis at day 1, nephrectomy day 3.
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o Eculizumab and regained almost normal renal function despite
ver 3 months of dialysis requirement. Three patients did not
ecover renal function. Mache et al. (2009) describe resolution
f the TMA and some renal recovery following a single dose of
culizumab, given 3 months after diagnosis of aHUS. Following a
elapse 2 weeks later, 3 more doses of Eculizumabwere given. This
gain corrected the TMA but the patient had developed ESRD and
culizumab was stopped. Kose et al. (2010) report initial control of
MA and renal improvement following a single dose of Eculizumab
ut a relapse after 2months led to ESRD. Garjau et al. (2012) report
ailure to recover renal function following initial treatmentwith PE
nd commencing treatmentwith Eculizumab 90 days after diagno-
is for a total of 27 weeks. The TMA, however, did improve.
Heinen et al. (2013) and Lapeyraque et al. (2011) report treat-
ent following a long relapsing-remitting coursehighlydependent
n PE. The period of plasma treatments had spanned 11 and 5
ears respectively. In the former case, a switch to Eculizumabmain-
ained TMA remission (though the patient already had established
SRD without improvement). In the latter case, PE resistant TMA
ad developed and Eculizumab successfully corrected TMA with
mprovement in renal function.
.5. Eculizumab in recurrent aHUS in renal transplantation
There are currently 15 reported cases of the use of Eculizumab
or the treatment of recurrence of aHUS in renal allografts (Table 2).
ine patients had documented mutations which are considered
igh risk for recurrence. The experience in early childhood is
imited – with only one child (6 years). The others ranged from
5 years to 43 years. Eight patients received Eculizumab within
ne month of disease recurrence. The longest time from recur-
ence to commencement of Eculizumab was 15 months. All, but
ne patient, received PE as part the treatment for recurrence
f aHUS (prior to receiving Eculizumab), including five patients
ho were on pre-emptive PE strategies. All patients responded to
culizumab, irrespective of their clinical course leading up to the
se of Eculizumab. Eight patients have remained on Eculizumab
nd have been in remission throughout.
Nurnberger et al. (2009) report giving a single dose of
culizumab resulting inearly remissionalthough thepatient subse-
uently lost their graft at 21months –without biopsy proven TMA.
na separate case, a singledose initially controlleddiseasebut aHUS
ecurred at 11 months necessitating reintroduction of Eculizumab
Larrea et al., 2010). Subsequent humoral rejection ultimately led
o graft loss.
In two reported cases (Alachkar et al., 2012; Zuber et al., 2012b)
culizumab initially controlled aHUS recurrence in the transplant
nd treatment was stopped at 8 months. One patient developed
neumonia 5 months after discontinuation of Eculizumab leading
o a relapse of aHUS and worsening renal function. Eculizumab
as recommenced resulting in improvement in TMA and renal
unction. Following an endovascular procedure, this patient devel-
ped severe acute tubular necrosis with poor recovery. Progressive
enal failure followed leading to graft loss after 2 years. Eculizumab
as only discontinued at this time-point – there was no evidence
f TMA throughout this time. The other patient had a relapse of
HUS 3 months after discontinuation of Eculizumab, triggered by
nfluenza vaccination. Eculizumabwas restarted and remission has
een maintained. In two further cases (Chatelet et al., 2010; Zuber
t al., 2012b) minor relapses followed delays in dosing. Zuber and
egendre (Zuber et al., 2012b) report one patient who had a low
aptoglobin level between 6 and 12 weeks of starting Eculizumab.
enal biopsy was therefore undertaken demonstrating fresh TMA
esions despite ongoing Eculizumab treatment. CH50 was below
he level of detection and renal allograft function was stable.unology 56 (2013) 199–212 207
9.6. Pre-emptive use of Eculizumab in renal transplantation
With the high aHUS recurrence rate in renal allografts in indi-
viduals with complement mutations, pre-emptive Eculizumab has
been given in ten cases (Table 3). All patients had a complement
mutation that is associated with a high risk of disease recurrence.
Two patients had PE prior to renal transplantation and contin-
ued until days 5 and 10 respectively before receiving Eculizumab.
Three patients had PE followed by Eculizumab pre-operatively and
the remaining five patients received only Eculizumab (no PE) at
the time of transplantation. Most (9/10) patients remain in dis-
ease remission (and still receiving Eculizumab)with excellent graft
function with follow-up ranging from 2 months to over 2 years.
Only 1 patient had graft loss and thiswas due to arterial thrombosis
in a patient with S1191L mutation in CFH.
9.7. Prospective trials
Although the results of the prospective trials have as yet,
only been reported in meeting abstracts (Greenbaum et al.,
2011; Greenbaum, 2011; Legendre et al., 2010; Licht, 2011; Licht
et al., 2011; Muus et al., 2010) from the information available,
Eculizumabseemshighlyeffective,with∼85%ofpatientsbecoming
disease free in both plasma-resistant and plasma-dependent aHUS
(reviewedZuber et al., 2011). It has been suggested that Eculizumab
achieves better control of disease as witnessed by improvement in
renal function following switching from PE and in rescuing plasma
resistant individuals (Zuber et al., 2011). It should be noted how-
ever that a randomised trial of Eculizumab against PE was not and
is unlikely to be performed.
9.8. Adverse effects of Eculizumab
There were few side effects documented in the review of the
case reports. Adverse effects were reported in preliminary data
from the prospective open-label clinical trials of Eculizumab in
aHUS. Campistol et al. (2013) summarise this data and note 4
reports (out of 37 patients) of serious adverse effects (peritoni-
tis, influenza infections, venous disorder and severe hypertension).
The use of Eculizumab has been approved for use in PNH fol-
lowing a successful clinical trial. In this study there were only 4
serious adverse effects (compared to 9 in placebo). These were
exacerbation of PNH, renal colic, lumbar- or sacral-disc prolapsed
and-haemolytic streptococcal bacteraemia (Hillmen et al., 2006).
Vaccination against Streptococcus pneumonia and Haemophilus
influenza B in children treated with Eculizumab has been recom-
mended (Zuber et al., 2011).
9.9. Risk of meningococcal infection
It is well recognised that loss of ability to form membrane
attack complex is associated with infection due to Neisseria menin-
gitidis. Patients receiving Eculizumab should therefore receive the
tetravalent vaccine (A,C,Y,W135). Because the vaccine does not
cover themost prevalent serogroup in Europe – serogroup B (Bouts
et al., 2011) we recommend ongoing prophylactic penicillin in
Eculizumab treated patients.
9.10. When to start Eculizumab?
We believe that there is a clear role for the use of Eculizumab
in the treatment of aHUS. Despite this PE should remain the initial
treatment in adults until ADAMTS13 deficiency can be excluded. In
paediatric cases where the risks and difficulties of administrating
PE are high, it has been suggested that Eculizumab be used first
line. The success of such a strategydepends on thedifferentiation of
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HUS fromTTP and the authors are aware of at least one casewhere
ongenital ADAMTS13 deficiencywould have been inappropriately
reated with Eculizumab (based on platelet count, creatinine and
linical presentation).
Given the apparent superior efficacy of Eculizumab over PE
Zuber et al., 2011), the authors believe that once ADAMTS13 defi-
iency has been excluded all patients should be managed with
culizumab. While genetic testing should be performed in all
atients with aHUS, it need not delay treatment with Eculizumab.
learly, the prohibitive cost of Eculizumab will mean that in many
arts of the World, PE remains the only available treatment.
In patients undergoing transplantationwith high riskmutations
e.g. CFH, C3 and CFB), the unavoidable ischaemia–reperfusion
njury induced complement activation make pre-emptive
culizumab the treatment of choice in our opinion.
The penetrance rate in families with mutations is low and as
uch there will be many family members potentially at risk of
isease when exposed to a triggering stimuli. Currently in family
embers with known mutations our strategy has been to advise
onitoring at times of high risk (e.g. pregnancy, respiratory tract
nfections, etc.).
.11. When to stop Eculizumab?
Ultimately, the aim is tobalance the riskof Eculizumab (see side-
ffects) against effective treatment and prevention of recurrence of
MA and the organ-specific damage associated with it. Early ces-
ation of Eculizumab has given rise to recurrence of disease. This
s perhaps unsurprising with a terminal cascade blocking agent,
s the C3 convertase will initially still be active on the glomeru-
ar vasculature. As such, a sustained course of treatment should be
iven to maintain inhibition of complement activity. The reported
xperiences suggest that even in individuals who have presented
equiring dialysis, Eculizumab treatment can control disease even-
ually leading to recovery of renal function after several months. It
s tempting to treat every patient with long-term Eculizumab, but
he cost and unknown long-term effects of this treatment need to
e considered. There are certain groups of individuals where with-
rawal of Eculizumab is likely to be successful (e.g.MCPmutations).
uch a strategy should be performedunder the auspices of a clinical
rial with careful monitoring.
Likewise in individuals treated with Eculizumab where genetic
nalysis subsequently revealsmutations inDGKε, treatment can be
topped. This pathway does not seem to involve the complement
ystem and as such complement modulatory therapy is unlikely to
e efficacious. Indeed, one patient with mutations in DGK ε devel-
ped aHUS while on treatment with Eculizumab (Lemaire et al.,
013).
In individuals where TMA has been controlled but renal func-
ion has not recovered Eculizumab has usually been discontinued.
here are, however, rare reports of severe extra-renal manifesta-
ions such as cerebral artery stenoses (Kaplan et al., 2000; Loirat
t al., 2010; Vergouwen et al., 2008) which have been attributed
o ongoing complement activation. The experience is currently too
imited to recommend routine ongoing treatmentwith Eculizumab
n individuals on long term dialysis.
.12. Single nucleotide polymorphisms in C5
It had been noted in a Japanese PNH population that cer-
ain individuals did not respond to Eculizumab despite adequate
erum levels (Nishimura et al., 2012). In vitro assays of these non-
esponders’ serum demonstrated an inability of Eculizumab to
revent haemolysis. An antibody against a different epitope on
5 did, however, block haemolysis. Genetic analysis of these non-
esponders revealed a SNP in C5 (p.R885H) which predicted a poorunology 56 (2013) 199–212
response to Eculizumab (Nishimura et al., 2012). This SNP was
present in around 2% of a Japanese population. In individuals with
aHUSwho fail to respond to Eculizumab, PE should be re-instituted
and genetic analysis of C5 performed.
9.13. Long term treatment with Eculizumab
While the effect of Eculizumab in preventing ESRD in aHUS
seems inescapable, long term follow up is still awaited. It is inter-
esting to note that an aHUS patientwho received the drug seems to
have deposited the Eculizumab in glomeruli and tubular basement
membranes (Herlitz et al., 2012). This has also been reported in
individuals receiving treatment for C3 glomerulopathies and DDD
where Eculizumab was deposited in a similar distribution and was
said to resemble monoclonal immunoglobulin deposition disease
(Herlitz et al., 2012). Similarly, as would be expected in a terminal
pathway blocking therapy, these individuals continued to deposit
C3 in the kidney (Herlitz et al., 2012). While the outcome of these
effects remains to be established, the longer term evidence from
PNH treatment would not suggest worsening of kidney function or
development of proteinuria (Hillmen et al., 2010).
10. Summary
In the last 15 years the elucidation of the role of complement
in pathogenesis of aHUS has seen a sea change in the management
of disease. The complement inhibitor, Eculizumab, has now been
demonstrated to be effective in controlling aHUS, however, its pro-
hibitive cost will mean that in many parts of the World, PE will
remain the only treatment option.
Added in press
The prospective trial of Eculizumab in aHUS demonstrating effi-
cacy has now been published (Legendre et al., 2013).
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